Table 1.
Clinical Data, Primary Lesion, and Histopathology of the Regional Lymph Nodes Selected for Immunocytochemical Analysis of ER Expression in GC Cells of 20 Patients
| Patient number | Sex | Age | Primary pathology | Number and pathology of LN with GC | Mean number of ER+ cells per GC |
|---|---|---|---|---|---|
| 1 | F | 86 | Colon adenocarcinoma | 3/Hyperplasia | 32 ± 5 |
| 2 | F | 45 | Breast IDC | 2/Metastasis | 12 ± 2 |
| 3 | F | 67 | Breast IDC | 1/Metastasis | 15 ± 2 |
| 4 | F | 51 | Breast IDC | 2/Metastasis | 28 ± 9 |
| 5 | F | 54 | Breast IDC | 3/Hyperplasia | 23 ± 3 |
| 6 | M | 58 | Skin melanoma | 3/Hyperplasia | 35 ± 7 |
| 7 | M | 66 | Gastric adenocarcinoma | 4/Hyperplasia | 8 ± 2 |
| 8 | M | 46 | Skin melanoma | 2/Hyperplasia | 14 ± 6 |
| 9 | F | 69 | Breast IDC | 4/Hyperplasia | 13 ± 7 |
| 10 | F | 79 | Breast ILC | 2/Metastasis | 41 ± 10 |
| 11 | F | 69 | Breast ILC | 2/Hyperplasia | 18 ± 2 |
| 12 | F | 63 | Breast IDC | 3/Hyperplasia | 49 ± 7 |
| 13 | F | 70 | Pancreas adenocarcinoma | 3/Hyperplasia | 28 ± 4 |
| 14 | F | 80 | Breast IDC | 1/Hyperplasia | 10 ± 2 |
| 15 | F | 36 | Latero cervical adenopathy | 1/Hyperplasia | 30 ± 8 |
| 16 | M | 23 | Peritoneal inflammation | 1/Hyperplasia | 11 ± 5 |
| 17 | F | 32 | Thyroid papillary carcinoma | 2/Hyperplasia | 36 ± 7 |
| 18 | M | 79 | Colon adenocarcinoma | 2/Hyperplasia | 20 ± 5 |
| 19 | M | 60 | Pancreas adenocarcinoma | 1/Hyperplasia | 21 ± 3 |
| 20 | F | 77 | Gallbladder inflammation | 1/Hyperplasia | 24 ± 3 |
IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; GC, germinal centers; LN, lymph node.